Related Experiment Video
Updated: Apr 5, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Drug-induced liver injury secondary to tirzepatide
Chester Yixuan Cao1,2, Deloshaan Subhaharan3,4, Peter Mikhail-Gouda3,4
1Department of Digestive Health, Gold Coast University Hospital, Southport, Queensland, Australia chester.cao@health.qld.gov.au.
Abstract:
Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicity is not a recognised complication. Recent case reports have emerged describing drug-induced liver injury associated with tirzepatide. We present a case of a woman aged in her 20s who developed acute hepatocellular injury within four weeks of commencing tirzepatide. Extensive investigations did not reveal an alternative cause of liver injury. Following the cessation of tirzepatide, the patient demonstrated clinical and biochemical recovery over the following four weeks.
More Related Videos
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Toxicity: Risk factors
Drug toxicity: Idiosyncratic Reactions
Therapeutic Drug Monitoring: Affecting Factors
Drug Toxicity: Overview
Drug toxicity: Drug–Drug Interaction